1. Nh-)-d, J. , J. , and H. =. , 09 (s, 1H, CDCl3) ?: 10.0880 Hz, 1H, H-9), pp.64-71

J. , H. =. 2h, J. , H. =. 1h, J. et al., 28 (m, 1H, H-8), 3.65 (s, 2H, CH2N), pp.38-45

2. Hz, 10-2.00 (m, 2H, CH2 pip, pp.0-91

2. Hz, J. , and H. =. , 46 (s, 2H, CH2N), p.52

2. , C. Pipt, J. , J. , and H. =. , 40 Hz, 2H, pp.2-158819

1. Nh-)-d and J. , 80 Hz, 2H, H-2' and H-6'), 7.67-7.57 (m, 6H, H-7, H-3 phenyl, H-4 phenyl, H-5 phenyl, H-3' and H-5'), 7.55 (s, 1H, CDCl3) ?: 10.19.05 (m, 4H, H-8, H-5 benzimid., H-6 benzimid., H-7 benzimid.), pp.30241-30248

J. , H. =. Jh, and H. =. , 29 (m, 3H, H-2 phenyl, H-6 phenyl and H-3 pyr, 00 Hz, 1H, H-8), 4.14 (q, JH,H = 7.10 Hz, 2H, OCH2), 3.67 (s, 2H, CH2N), pp.40-707

M. Falasca, PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs, Current Pharmaceutical Design, vol.16, issue.12, pp.1410-1416, 2010.
DOI : 10.2174/138161210791033950

M. Hanada, J. Feng, and B. A. Hemmings, Structure, regulation and function of PKB/AKT???a major therapeutic target, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, vol.1697, issue.1-2, pp.3-16, 2004.
DOI : 10.1016/j.bbapap.2003.11.009

]. C. Kumar and V. Madison, AKT crystal structure and AKT-specific inhibitors, Oncogene, vol.62, issue.50, pp.7493-7501, 2005.
DOI : 10.1016/j.bmcl.2004.12.062

]. X. Huang, M. Begley, K. A. Morgenstern, Y. Gu, P. Rose et al., Crystal Structure of an Inactive Akt2 Kinase Domain, Structure, vol.11, issue.1, pp.21-30, 2003.
DOI : 10.1016/S0969-2126(02)00937-1

]. C. Garcia-echeverria and W. R. Sellers, Drug discovery approaches targeting the PI3K/Akt pathway in cancer, Oncogene, vol.64, issue.41, pp.5511-5526, 2008.
DOI : 10.1038/onc.2008.246

]. D. Brazil and B. A. Hemmings, Ten years of protein kinase B signalling: a hard Akt to follow, Trends in Biochemical Sciences, vol.26, issue.11, pp.657-664, 2001.
DOI : 10.1016/S0968-0004(01)01958-2

]. K. Nicholson and N. G. Anderson, The protein kinase B/Akt signalling pathway in human malignancy, Cellular Signalling, vol.14, issue.5, pp.381-395, 2002.
DOI : 10.1016/S0898-6568(01)00271-6

I. Vivanco and C. L. Sawyers, The phosphatidylinositol 3-Kinase???AKT pathway in human cancer, Nature Reviews Cancer, vol.2, issue.7, pp.489-501, 2002.
DOI : 10.1038/nrc839

S. Barnett, M. Bilodeau, and C. Lindsley, The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation, Current Topics in Medicinal Chemistry, vol.5, issue.2, pp.109-125, 2005.
DOI : 10.2174/1568026053507714

G. Zhu, J. Gong, V. B. Gandhi, K. Woods, Y. Luo et al., Design and synthesis of pyridine???pyrazolopyridine-based inhibitors of protein kinase B/Akt, Bioorganic & Medicinal Chemistry, vol.15, issue.6, pp.2441-2452, 2007.
DOI : 10.1016/j.bmc.2007.01.010

C. Lindsley, The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation: A 2009 Update, Current Topics in Medicinal Chemistry, vol.10, issue.4, pp.458-477, 2010.
DOI : 10.2174/156802610790980602

I. Collins, Targeted Small-Molecule Inhibitors of Protein Kinase B as Anticancer Agents, Anti-Cancer Agents in Medicinal Chemistry, vol.9, issue.1, pp.32-50, 2009.
DOI : 10.2174/187152009787047734

I. M. Ghobrial, A. Roccaro, F. Hong, E. Weller, N. Rubin et al., Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia, Clinical Cancer Research, vol.16, issue.3, pp.1033-1074, 2010.
DOI : 10.1158/1078-0432.CCR-09-1837

S. Barnett, D. Defeo-jones, S. Fu, P. Hancock, K. Haskell et al., Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors, Biochemical Journal, vol.385, issue.2, pp.399-408, 2005.
DOI : 10.1042/BJ20041140

C. W. Lindsley, Z. Zhao, W. H. Leister, R. G. Robinson, S. F. Barnett et al., Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors, Bioorganic & Medicinal Chemistry Letters, vol.15, issue.3, pp.761-764, 2005.
DOI : 10.1016/j.bmcl.2004.11.011

Y. Li, J. Liang, T. Siu, E. Hu, M. A. Rossi et al., Allosteric inhibitors of Akt1 and Akt2: Discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity, Bioorganic & Medicinal Chemistry Letters, vol.19, issue.3, pp.834-836, 2009.
DOI : 10.1016/j.bmcl.2008.12.017

J. Guillon, I. Forfar, M. Mamani-matsuda, V. Desplat, M. Saliège et al., Synthesis, analytical behaviour and biological evaluation of new 4-substituted pyrrolo[1,2-a]quinoxalines as antileishmanial agents, Bioorganic & Medicinal Chemistry, vol.15, issue.1, pp.194-210, 2007.
DOI : 10.1016/j.bmc.2006.09.068

J. Guillon, E. Mouray, S. Moreau, C. Mullié, I. Forfar et al., New ferrocenic pyrrolo[1,2-a]quinoxaline derivatives: Synthesis, and in vitro antimalarial activity ??? Part II, European Journal of Medicinal Chemistry, vol.46, issue.6, pp.2310-2326, 2011.
DOI : 10.1016/j.ejmech.2011.03.014

V. Desplat, A. Geneste, M. Begorre, S. B. Fabre, S. Brajot et al., ]quinoxaline Derivatives as Potential Inhibitors of Akt Kinase, Journal of Enzyme Inhibition and Medicinal Chemistry, vol.2, issue.5, pp.648-658, 2008.
DOI : 10.1021/jm990151g

V. Desplat, S. Moreau, A. Gay, S. B. Fabre, D. Thiolat et al., Synthesis and evaluation of the antiproliferative activity of novel pyrrolo[1,2-a]quinoxaline derivatives, potential inhibitors of Akt kinase. Part II, Journal of Enzyme Inhibition and Medicinal Chemistry, vol.4, issue.2, pp.204-215, 2010.
DOI : 10.1080/00397919508015898

V. Desplat, S. Moreau, S. Belisle-fabre, D. Thiolat, J. Uranga et al., ]quinoxaline derivatives, Journal of Enzyme Inhibition and Medicinal Chemistry, vol.18, issue.5, pp.657-667, 2011.
DOI : 10.1016/j.intimp.2006.08.009

URL : https://hal.archives-ouvertes.fr/hal-01307573

U. Schneider, H. U. Schwenk, and G. Bornkamm, Characterization of EBV-genome negative ???null??? and ???T??? cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma, International Journal of Cancer, vol.140, issue.5, pp.621-626, 1977.
DOI : 10.1002/ijc.2910190505

E. Klein, F. Vánky, H. Ben-bassat, H. Neumann, P. Ralph et al., Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia, International Journal of Cancer, vol.1, issue.4, pp.421-431, 1976.
DOI : 10.1002/ijc.2910180405

S. Kamijo, C. Kanazawa, and Y. Yamamoto, Copper- or Phosphine-Catalyzed Reaction of Alkynes with Isocyanides. Regioselective Synthesis of Substituted Pyrroles Controlled by the Catalyst, Journal of the American Chemical Society, vol.127, issue.25, pp.9260-9266, 2005.
DOI : 10.1021/ja051875m

A. Gulevich, A. G. Zhdanko, R. V. Orru, and V. G. Nenajdenko, Isocyanoacetate Derivatives: Synthesis, Reactivity, and Application, Chemical Reviews, vol.110, issue.9, pp.5235-5331, 2010.
DOI : 10.1021/cr900411f

M. Suzuki, M. Miyoshi, and K. Matsumoto, Synthesis of amino acids and related compounds. 7. Convenient synthesis of 3-substituted pyrrole-2,4-dicarboxylic acid esters, The Journal of Organic Chemistry, vol.39, issue.13, pp.1980-1980, 1974.
DOI : 10.1021/jo00927a056

S. Ngwerume and J. E. Camp, Synthesis of Highly Substituted Pyrroles via Nucleophilic Catalysis, The Journal of Organic Chemistry, vol.75, issue.18, pp.6271-6274, 2010.
DOI : 10.1021/jo1011448

B. A. Trofimov, Preparation of Pyrroles from Ketoximes and Acetylenes, Adv. Heterocycl. Chem, vol.51, pp.177-301, 1990.
DOI : 10.1016/S0065-2725(08)60003-3